Revolution Medicines, Inc. (RVMD)
165.13
+5.70
(+3.58%)
USD |
NASDAQ |
Nov 20, 10:00
Revolution Medicines Cash from Operations (Quarterly) : -415.65M for Sept. 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | -415.65M |
| June 30, 2026 | -387.32M |
| March 31, 2026 | -354.16M |
| December 31, 2025 | -274.24M |
| September 30, 2025 | -207.31M |
| June 30, 2025 | -221.76M |
| March 31, 2025 | -194.44M |
| December 31, 2024 | -138.29M |
| September 30, 2024 | -130.42M |
| June 30, 2024 | -128.17M |
| March 31, 2024 | -160.56M |
| December 31, 2023 | -120.56M |
| September 30, 2023 | -100.50M |
| June 30, 2023 | -67.12M |
| March 31, 2023 | -62.39M |
| December 31, 2022 | -61.79M |
| Date | Value |
|---|---|
| September 30, 2022 | -51.74M |
| June 30, 2022 | -55.72M |
| March 31, 2022 | -55.16M |
| December 31, 2021 | -39.26M |
| September 30, 2021 | -36.59M |
| June 30, 2021 | -34.08M |
| March 31, 2021 | -37.25M |
| December 31, 2020 | -25.03M |
| September 30, 2020 | -27.02M |
| June 30, 2020 | -19.99M |
| March 31, 2020 | -28.02M |
| December 31, 2019 | |
| September 30, 2019 | |
| June 30, 2019 | -11.50M |
| March 31, 2019 | -12.60M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Moderna, Inc. | -1.559B |
| Oncolytics Biotech, Inc. | -6.754M |
| Intellia Therapeutics, Inc. | -85.43M |
| Twist Bioscience Corp. | -0.173M |
| Beam Therapeutics, Inc. | -110.75M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | 80.10M |
| Cash from Financing (Quarterly) | 147.00M |
| Free Cash Flow | -1.441B |
| Free Cash Flow Per Share (Quarterly) | -1.951 |
| Free Cash Flow to Equity (Quarterly) | -440.29M |
| Free Cash Flow to Firm (Quarterly) | -385.74M |
| Free Cash Flow Yield | -4.03% |